Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075745 · ClinicalTrials.gov registry record · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
A Phase 2 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 416
- Enrollment target
- 18
- Study locations
NCT06075745: Recruiting Phase 2 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06075745 is a Phase 2 study of Liver Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 416 participants, below the 5,436-participant average among 19 other Liver Transplant trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075745, a Phase 2 study of Liver Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 416 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (LTxRs). A protocol-mandated preemptive therapy (PET) will be used for CMV disease prevention in D+R- LTxRs.
Conditions Studied
Interventions
- DRUG CMV-MVA Triplex
- DRUG Placebo for CMV-MVA Triplex
Study Locations (18)
California
- University of California, San Diego School of Medicine - La Jolla
- Stanford University - Redwood City
- University of California, San Francisco - San Francisco
Pennsylvania
- University of Pennsylvania School of Medicine - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama at Birmingham, School of Medicine - Birmingham
Florida
- University of Miami, Jackson Memorial Hospital - Miami
Georgia
- Emory University Hospital - Atlanta
Illinois
- Northwestern University, Feinberg School of Medicine - Chicago
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Michigan
- University of Michigan Medical Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 2 |
What NCT06075745 shows while recruiting
NCT06075745 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, below the 5,436-participant average among 19 other Liver Transplant trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 2 interventions - of which CMV-MVA Triplex is the first listed.
NCT06075745 lists 18 locations in 15 states (California, Pennsylvania, Alabama).
Frequently Asked Questions
What is clinical trial NCT06075745 about?
NCT06075745 is a clinical study titled "Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates". This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-tr...
What is the current status of trial NCT06075745?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2024-03-05. Estimated completion is 2028-02-28.
What conditions does trial NCT06075745 study?
This clinical trial studies the following conditions: Liver Transplant.
What interventions are being tested in trial NCT06075745?
The interventions under investigation include: CMV-MVA Triplex (DRUG), Placebo for CMV-MVA Triplex (DRUG).
Who is sponsoring clinical trial NCT06075745?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075745 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06075745's enrollment target sits among peer trials
416 3rd of 19 higher than 17 of 19 other Liver Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
RECRUITING · Phase 2
-
Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue
RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
COMPLETED · Phase 2
-
US National OCS Liver Perfusion (OLP) Registry
RECRUITING
-
Liver Transplant CGM
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06111040 · 416 participants · NA
Nurturing Needs Study: Parenting Food Motivated Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI